Skip to main content

Table 2 Specialties of providers primarily prescribing and managing systemic bevacizumab for HHT-related HOCF in HHT centers

From: Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

Specialty

Percent of Centers

Hematology

50%

Pulmonology

39%

Cardiology

11%

Gastroenterology

6%

Internal Medicine

6%

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172